Department of Clinical Research

Jivanrekha Multispeciality Hospital

Infections

Communicable Diseases

COVID-19

RP7214

Rhizen Pharmaceuticals

Vedic Lifesciences

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The goal of this clinical trial is to study the impact of VL-NL-02 in improving sleep quality, restorative sleep complaints, quality of life, stress levels, and sleep stages.

48 participants are expected to be randomized in a ratio of 1:1 to receive either VL-NL-02 or placebo and will be assigned a unique randomization code. Each group will have at least 20 completed participants after accounting for a dropout/withdrawal rate of 17%. The intervention duration for all the study participants is 21 days.

Participants will be asked to fill multiple questionnaires to assess sleep quality and mood imbalance.

A Study to Evaluate the Efficacy of VL-NL-02 on Sleep Quality.

Jivanrekha Multispeciality Hospital | Department of Clinical Research

Site insights

Work at this site?

Active trials

A Study to Evaluate the Efficacy of VL-NL-02 on Sleep Quality.

Trial sponsors